Showing results (31-40 of 170) with videos related to
Sort By:
Pageof 17
AIDS and Behavior|February 10, 2015
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic SettingNivashnee Naicker, Ayesha B M Kharsany, Lise Werner, et al.Eclinicalmedicine|December 9, 2020
Cost-effectiveness of adoption strategies for point of care HIV viral load monitoring in South AfricaSarah J Girdwood, Thomas Crompton, Monisha Sharma, et al.International Journal of STD & AIDS|June 14, 2026
Diagnostic accuracy of the Xpert HPV assay in women starting antiretroviral treatment in South AfricaNivashnee Naicker, Lenine Liebenberg, Kunthi Naidoo, et al.Antimicrobial Agents and Chemotherapy|July 19, 2021
Antimicrobial Resistance Mechanisms, Multilocus Sequence Typing, and NG-STAR Sequence Types of Diverse Neisseria gonorrhoeae Isolates in KwaZulu-Natal, South AfricaNireshni Mitchev, Ravesh Singh, Mushal Allam, et al.AIDS and Behavior|December 26, 2013
Health-related quality of life dynamics of HIV-positive South African women up to ART initiation: evidence from the CAPRISA 002 acute infection cohort studyAndrew Tomita, Nigel Garrett, Lise Werner, et al.Journal of Virology|June 27, 2022
HIV Coinfection Provides Insights for the Design of Vaccine Cocktails to Elicit Broadly Neutralizing AntibodiesDaniel J Sheward, Tandile Hermanus, Ben Murrell, et al.International Journal of STD & AIDS|September 26, 2023
Incidence of herpes simplex virus type 2 positivity among women living with human immunodeficiency virus in South AfricaKwabena Asare, Sinaye Ngcapu, Farzana Osman, et al.Southern African Journal of HIV Medicine|May 13, 2025
Rapid emergence of dolutegravir resistance on second-line dolutegravir-based ARTKirusha Naidoo, Richard J Lessells, Jienchi Dorward, et al.BMJ Open|February 21, 2019
Diagnostic accuracy of the Xpert CT/NG and OSOM Trichomonas Rapid assays for point-of-care STI testing among young women in South Africa: a cross-sectional studyNigel Garrett, Nireshni Mitchev, Farzana Osman, et al.The Lancet. HIV|June 10, 2018
Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and researchJienchi Dorward, Richard Lessells, Paul K Drain, et al.Pageof 17